Hepatosplenic T cell lymphoma responsive to 2′-deoxycoformycin therapy

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 727-729

  Bennett, Michael ^a   Matutes, Estella ^b   Gaulard, Philippe ^c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PENTOSTATIN;

FEMALE; HUMAN; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MIDDLE AGED; PATHOLOGY; REMISSION; SPLENIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOMA, T-CELL; MIDDLE AGED; PENTOSTATIN; REMISSION INDUCTION; SPLENIC NEOPLASMS;

EID: 77956472714     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21774     Document Type: Article

References (17)

1. Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: Sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 1990;75:2213-2219. (Pubitemid 20181173)
2. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: A report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001;25:285-296. (Pubitemid 32174197)
3. Suarez F, Wlodarska I, Rigal-Huguet F, et al. Hepatosplenic alphabeta T-cell lymphoma: An unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma. Am J Surg Pathol 2000;24:1027-1032. (Pubitemid 30430492)
4. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; IARC:Lyon, France: 2008.
5. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265-4274. (Pubitemid 26399174)
6. Felgar RE, Macon WR, Kinney MC, et al. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997;150:1893-1900.
7. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: Evidence of origin from lymphocytes involved in innate immunity. Blood 2003;101:3590-3593.
8. Alonsozana EL, Stamberg J, Kumar D, et al. Isochromosome 7q: The primary cytogenetic abnormality in hepatosplenic gammadelta T cell lymphoma. Leukemia 1997;11:1367-1372.
9. Wlodarska I, Martin-Garcia N, Achten R, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 2002;33:243-251.
10. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003;102:4261-4269.
11. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000;14:991-997.
12. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Ann Oncol 2009;20:1080-1085.
13. Chin M, Mugishima H, Takamura M, et al. Hemophagocytic syndrome and hepatosplenic gammadelta T-cell lymphoma with isochromosome 7q and 8 trisomy. J Pediatr Hematol Oncol 2004;26:375-378.
14. Nosari A, Oreste PL, Biondi A, et al. Hepato-splenic gammadelta T-cell lymphoma: A rare entity mimicking the hemophagocytic syndrome. Am J Hematol 1999;60:61-65.
15. Weirich G, Sandherr M, Fellbaum C, et al. Molecular evidence of bone marrow involvement in advanced case ot Tgammadelta lymphoma with secondary myelofibrosis. Hum Pathol 1998;29:761-765.
16. Morice WG, Macon WR, Dogan A, et al. NK-cell-associated receptor expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia 2006;20:883-886.
17. Aldinucci D, Poletto D, Zagonel V, et al. In vitro and in vivo effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. Br J Haematol 2000;110:188-196.